neurological conditions

Members of the back the one in six hand-in delegation stand together. Big Ben is in the background.
June 13, 2024

Neurological Alliance launches #NeuroChampion campaign ahead of UK 2024 General Election

As the UK prepares for the upcoming General Election on 4 July 2024, The Neurological Alliance and our members are launching a pivotal campaign to call on future MPs to use their voice to improve treatment, care, support and research for people affected by neurological conditions. Parliamentary support has never been more needed The #NeuroChampion […]
April 4, 2024

NHS England Operational Planning Guidance for 24/25 published

Last week, just days before the new financial year, NHS England published its Priorities and Operational planning guidance for 2024/25. You can read the full document here. The document outlines key priorities for NHS spending and focus for the year ahead.  The guidance is important, as it sets out key areas of activity for the […]
April 2, 2024

Neurological conditions leading cause of ill health and disability globally

New research published in The Lancet Neurology has confirmed that neurological conditions are now the leading cause of ill health and disability globally. More than four in 10 of the world population lived with a neurological condition in 2021, approximately 3.4 billion people. 443 million years of healthy life lost Researchers calculated the overall “burden” […]
March 6, 2024

Unpacking the 2024 England Rare Disease Action Plan 

Rare Disease Day 2024 (29/02/2024) saw the publication of the third England Rare Disease Action Plan. Rare conditions are individually rare but collectively common, affecting 1 in 17 people in the UK at some point in their lifetime. Almost half of the 7,000 known rare conditions are neurological. The latest action plan builds on the […]
February 27, 2024

Too costly to wait: provide care and support now and reduce the economic impact of neurological conditions

Blog by Georgina Carr, Chief Executive of The Neurological Alliance. This week new research from the Economist Unit, sponsored by Roche, found that neurological conditions cost at least £96 billion annually – and that these costs could be reduced by more than £30 billion, if care was improved, and existing options for treatment and care […]
February 27, 2024

New research shows that implementing existing solutions could reduce the financial impact of neurological conditions by £30 billion

New research released this week shows that neurological conditions are costing the UK 4.3% of its GDP, equivalent to £96 billion a year.1 The report, produced by The Economist Impact Unit and commissioned by pharmaceutical company Roche, suggests that implementing existing interventions could reduce the financial impact of these conditions by £30.8 billion.1 Implementing existing […]